{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Ascentage Pharma Group International"},"Symbol":{"label":"Symbol","value":"AAPG"},"Address":{"label":"Address","value":"68 XINQING ROAD,SUZHOU INDUSTRIAL PARK, SUZHOU, China"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Asia"},"CompanyDescription":{"label":"Company Description","value":"Ascentage Pharma Group is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Our lead assets, olverembatinib and lisaftoclax, have global potential to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. We are the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. We have eleven completed or ongoing U.S. and/or international registrational trials, including two that are FDA-regulated, for our five key clinical-stage assets."},"CompanyUrl":{"label":"Company Url","value":"https://www.ascentagepharma.com"}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}